Patent · US Active

SSX-2 peptide analogs

US8202841B2 · kind B2 · utility

2Cited by
22References
41Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 17, 2005
Grant dateJun 19, 2012
Priority date
Expiry dateSep 10, 2029

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K38/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.